Technical Data
C7850-28
C5b-9 Terminal Complement Complex (TCC, MAC complex) (FITC)
Description:
C5b-9 is also known as the terminal complement complex (TCC). The TCC consists of C5b, C6, C7, C8and C9 and forms the membrane attack complex (MAC) as well as the non-lytic fluid-phase SC5b-9 complex (with protein S). The MAC forms channels in target cell membranes leading to cell lysis by osmotic leakage. The complexes contain neoantigens that are absent from the individual nativecomponents from which they are formed.

Applications:
Suitable for use in ELISA, Immunofluorescence and Immunohistochemistry. Not suitable for Western Blot. Other applications have not been tested.

Recommended Dilutions:
Immunohistochemistry: Frozen and paraffin sections
Optimal dilutions to be determined by the researcher.

Culture Medium:
RPMI 1640 with 10% fetal calf serum

Hybridoma:
X63.Ag8.653 myeloma cells with spleen cells from Balb/c mice.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
MabIgG2a,k13A37Affinity Purified
SizeStorageShippingSourceHost
100ul-20CBlue IceHumanMouse
Concentration:
~1mg/ml
Immunogen:
Purified C5b-9
Purity:
Purified by Protein A affinity chromatography.
Form
Supplied as a liquid in PBS. Labeled with fluorescein isothiocyanate (FITC).
Specificity:
Recognizes a neoepitope exposed on human C9 when incorporated into the TCC. Binds both membrane-bound MAC and fluid-phase SC5b-9 complexes. Species Crossreativity: porcine, baboon and equine.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Mollnes, T et al; Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 1985, 22: 197. 2. Mollnes, T et al; Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma. Scand J Immunol 1985, 22:183. 3. Pettersen, H et al; Human alveolar macrophages synthesize active complement components C6, C7, and C8 in vitro. Scand J Immunol 1987, 25: 567. 4. Berstad, A et al ; Epithelium related deposition of activated complement in Helicobacter pylori associated gastritis. Gut 1997, 40:196. 5. Stewart, M et al. Antiphospholipid antibody-dependent C5b-9 formation. BJH 1997, 96:451. 6. Meuwissen, M et al. Colocalisation of intraplauq C reactive protein, complement, oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction. J Clin Path 2005, 59:126.